Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals, a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen® (patented nicotinamide riboside, NR) for the Company’s Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joi